Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons

J Neurochem. 2004 Sep;90(5):1094-103. doi: 10.1111/j.1471-4159.2004.02574.x.

Abstract

Nicotine, acting on nicotinic acetylcholine receptors (nAChRs) expressed at pre-synaptic dopaminergic terminals, has been shown to stimulate the release of dopamine in the neostriatum. However, the molecular consequences of pre-synaptic nAChR activation in post-synaptic neostriatal neurons are not clearly understood. Here, we investigated the effect of nAChR activation on dopaminergic signaling in medium spiny neurons by measuring phosphorylated DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa) at Thr34 (the PKA-site) in mouse neostriatal slices. Nicotine produced dose-dependent responses, with a low concentration (1 microm) causing a sustained decrease in DARPP-32 Thr34 phosphorylation and a high concentration (100 microm) causing a transient increase in DARPP-32 Thr34 phosphorylation. Depending on the concentration of nicotine, either dopamine D2 or D1 receptor signaling was predominantly activated. Nicotine at a low concentration (1 microm) activated dopamine D2 receptor signaling in striatopallidal/indirect pathway neurons, likely by activating alpha4beta2* nAChRs at dopaminergic terminals. Nicotine at a high concentration (100 microm) activated dopamine D1 receptor signaling in striatonigral/direct pathway neurons, likely by activating (i) alpha4beta2* nAChRs at dopaminergic terminals and (ii) alpha7 nAChRs at glutamatergic terminals, which, by stimulating the release of glutamate, activated NMDA/AMPA receptors at dopaminergic terminals. The differential effects of low and high nicotine concentrations on D2- and D1-dependent signaling pathways in striatal neurons may contribute to dose-dependent actions of this drug of abuse.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology
  • Animals
  • Benzazepines / pharmacology
  • Blotting, Western / methods
  • Bungarotoxins / pharmacology
  • Cyclosporine / pharmacology
  • Dihydro-beta-Erythroidine / pharmacology
  • Dizocilpine Maleate / pharmacology
  • Dopamine Antagonists / pharmacology
  • Dopamine and cAMP-Regulated Phosphoprotein 32
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Enzyme Inhibitors / pharmacology
  • Excitatory Amino Acid Antagonists / pharmacology
  • In Vitro Techniques
  • Male
  • Mecamylamine / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Models, Neurological
  • Neostriatum / cytology*
  • Neostriatum / drug effects
  • Nerve Tissue Proteins / metabolism
  • Neurons / drug effects*
  • Neurons / metabolism
  • Nicotine / pharmacology*
  • Nicotinic Agonists / pharmacology*
  • Nicotinic Antagonists / pharmacology
  • Phosphoproteins / metabolism
  • Phosphorylation / drug effects
  • Raclopride / pharmacology
  • Receptors, Dopamine D1 / metabolism*
  • Receptors, Dopamine D2 / metabolism*
  • Tetrodotoxin / pharmacology
  • Threonine / metabolism

Substances

  • Benzazepines
  • Bungarotoxins
  • Dopamine Antagonists
  • Dopamine and cAMP-Regulated Phosphoprotein 32
  • Enzyme Inhibitors
  • Excitatory Amino Acid Antagonists
  • Nerve Tissue Proteins
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • Phosphoproteins
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Dihydro-beta-Erythroidine
  • Threonine
  • Raclopride
  • Tetrodotoxin
  • Mecamylamine
  • Dizocilpine Maleate
  • Nicotine
  • 6-Cyano-7-nitroquinoxaline-2,3-dione
  • Cyclosporine